News | February 14, 2025
IOL Chemicals and Pharmaceuticals reports Q3 FY25 revenue at Rs. 527.37 Cr
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
This collaboration aims to bridge modern scientific research with traditional Ayurvedic wisdom, fostering innovative solutions that support holistic well-being
_256_384.jpg)
Mesalazine is used to treat inflammatory bowel disease
Total Income in Q2 FY25 stood at Rs. 532.18 crore
Construction of the plant will commence in 2025 with first production expected to be in 2027
The new range incorporates a product that also contains the S-PRG filler employed in the Giomer range
The company uses iPS cells to develop treatments for diseases relating to the kidney
The company can now expand its business horizon into the area of pharmaceutical applications in the USA
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
EDQM has also issued a Certificate of Suitability for Allopurino
Subscribe To Our Newsletter & Stay Updated
